The FDA’s failures are a result of too much regulatory dithering and bureaucracy. Yet the Times’ prescriptions for change would just increase the dose.
American consumers deserve fair prices for our excellent health care. But lawmakers won’t deliver those prices by trying to control the market.
Many innovative, low-tech approaches to medicine help patients and help reduce the frequency of hospitalizations and, therefore, health care costs.
Chris Jacobs joins the Federalist Radio Hour to discuss his new book, “The Case Against Single Payer: How ‘Medicare for All’ Will Wreck America’s Health Care System.”
In the United States, antimicrobial resistance causes more than 2 million infections and 23,000 deaths per year—the equivalent of a Boeing 747 crashing each week.
As much as transgender ideologues disguised as doctors want to claim otherwise, some drugs pose serious and lasting risks to children.
If the ‘purpose of this regulation’ is to affect pharmaceutical pricing, then confining disclosures only to television advertisements would by definition have a limited impact.
Very few lawsuits against opioid makers were brought by victims or their families. Instead, they are being filed by cities, state’s attorneys general, and even Native American tribal councils.
The administration proposes changing the FDA’s name to the ‘Federal Drug Administration,’ making clear that its focus will solely be on drugs, devices, biologics, and tobacco.
While such costs represent a small fraction of overall spending on health care, several dynamics help the prescription drug issue gain disproportionate attention.
A Congressional Budget Office (CBO) document released quietly on Thursday hinted at a major gaffe by the budget agency and its efforts to conceal that gaffe.
Here’s a solution: stop focusing on trying to control prescription drug prices, and start paying attention to who’s paying them.
Reason Reporter Mike Riggs joins Federalist Radio to share the latest news and drug policy we are seeing from the new FDA commissioner.
A major anti-addiction nonprofit organization is getting big bucks from the pharmaceutical industry. Whose interests are the American Society of Addiction Medicine serving?
Danish researchers have found there are approximately 13 additional breast cancer cases for every 100,000 women who use hormonal contraception for one year.
The rising costs of many, if not all, medications are largely the result of the lack of competition in the pharmaceutical industry. That’s the FDA’s fault.
While the public hold little sympathy for Big Pharma, when the drug industry suffers, people suffer. And when Big Pharma wins, people win.
With his experience and highly competent past FDA leadership, Trump nominee Scott Gottlieb will oversee all the FDA divisions with better scrutiny than the prior commissioner did.
- The Senate’s Plan To Save Small Businesses Is Already Failing, And Mnuchin Just Made It WorseThe details are out of Treasury now, and it looks like continue reading >
- Trump Was Right, Cuomo Was Wrong About Ventilator NeedsThe media treated Cuomo's claims of needing 30,000 ventcontinue reading >
- Chuck Todd Is Wrong (Again): There Are Huge Downsides To The Media Being Overly AlarmistA good leader should balance what the coronavirus-limitcontinue reading >